Structural Dynamics of Incretin Receptors: Cryo-EM Insights into GLP-1R, GIPR, and GCGR Binding Mechanisms

 

Cryo-electron microscopy (cryo-EM) has transformed the study of class B1 G protein-coupled receptors (GPCRs), providing near-atomic resolution structures that reveal how the incretin receptors—GLP-1R, GIPR, and GCGR—recognise peptide hormones and transduce signals across the membrane. These three receptors form the central endocrine network that regulates insulin sensitivity and energy homeostasis, and their structural characterisation has become increasingly urgent as multi-agonist therapeutics enter clinical use. Recent cryo-EM studies have illuminated not only the conserved architecture of peptide recognition but also the receptor-specific conformational dynamics that underlie ligand selectivity and signalling bias.

The Conserved Two-Domain Binding Architecture

All three incretin receptors share a characteristic two-domain architecture: a large extracellular domain (ECD) connected by a flexible stalk to a seven-transmembrane domain (TMD). The general mechanism of peptide recognition follows a two-step model in which the peptide C-terminus first engages the ECD, positioning the peptide N-terminus for insertion into the TMD binding pocket. The GIPR structure at 2.9 Å resolution showed that GIP has a single straight helix. The N-terminus of GIP is in the receptor TMD, and the C-terminus is close to the ECD and extracellular loop 1 (ECL1).

The GLP-1R structures bound to GLP-1 and the biased agonist exendin-P5 similarly show the peptide N-terminus reaching deep into the TMD pocket, with the ECD capping the peptide from above. The GCGR structures with glucagon and dual-agonist peptides support this pattern, showing that the two-domain model is a common feature of class B1 GPCR activation.

Receptor-Specific Conformational Signatures

Despite the conserved binding architecture, cryo-EM comparisons reveal striking receptor-specific differences. Pairwise structural comparisons of GLP-1R and GIPR bound to their native ligands show Cα root mean square deviations (RMSDs) of 1.27–2.00 Å for GLP-1R and 1.52–1.80 Å for GIPR, indicating that each receptor adopts distinct conformational states even when bound to homologous peptides. These differences cluster in the extracellular loops—particularly ECL1, ECL2, and ECL3—and the upper regions of the transmembrane helices, which together form the receptor-specific ligand recognition surface.

The GIPR structure reveals a particularly instructive mechanism of ligand selectivity. The receptor employs conserved residues in the lower half of the TMD pocket to recognise segments shared by GIP and related peptides, while non-conserved residues in the upper half of the pocket interact with residues unique to GIP. This division of labour—conserved recognition at the bottom, specific discrimination at the top—provides a structural basis for the exquisite selectivity of GIP for its cognate receptor over other class B1 GPCRs.

Extracellular Loop 3 as a Signalling Switch

A major advance from recent cryo-EM studies is the identification of extracellular loop 3 (ECL3) as a critical determinant of signalling bias. Comparing GLP-1R structures bound to GLP-1 (balanced agonist), oxyntomodulin (β-arrestin-biased), and exendin-P5 (G protein-biased) revealed a striking pattern: only the G protein-biased agonist induces outward displacement of ECL3 away from the ligand-binding pocket. This conformational change was proposed to act as an "extracellular switch" linking ligand engagement to transducer selectivity.

The structural basis for this switch has been traced to interactions between the peptide N-terminus and ECL3. In the GLP-1R bound to tirzepatide, a dual GIP/GLP-1 agonist, the N-terminal tyrosine residue (Y1) disrupts a stable interaction between transmembrane helix 5 (TM5) and ECL3, contributing to G protein-biased signalling at GLP-1R. . Mutating this residue to histidine (Y1H) restores the TM5–ECL3 interaction and enables β-arrestin recruitment, confirming the structural link between ECL3 conformation and signalling bias.

The Lipidated Peptide Extension and Receptor Dynamics

Beyond the core peptide sequence, the lipidation of therapeutic peptides introduces additional structural complexity. Tirzepatide and related multi-agonists carry a C20 fatty diacid moiety attached via a linker to a lysine residue in the peptide's mid-region. Cryo-EM structures of tirzepatide-bound GIPR and GLP-1R reveal that this lipid moiety occupies a crevice between TM1 and TM2, establishing extensive contacts with receptor residues. Molecular dynamics simulations show that the acyl chain remains stably associated with this region, while the linker exhibits dynamic conformational sampling.

The lipid moiety appears to serve dual functions: extending plasma half-life through albumin binding and modulating receptor pharmacology. Comparisons of acylated and non-acylated tirzepatide reveal nearly identical receptor backbone conformations (Cα RMSDs of 0.6–0.7 Å), suggesting that the lipid primarily affects peptide-receptor interaction dynamics rather than gross receptor structure. This subtlety highlights how cryo-EM, when combined with molecular dynamics, can resolve functional contributions that static structures alone might miss.

G Protein Coupling and Intracellular Conformational Changes

The intracellular face of the receptor undergoes substantial reorganisation upon agonist binding. All three receptors show the hallmark outward movement of TM6 that creates the cavity for Gs protein engagement. The conserved HETY motif (H6.50, E6.53, T6.42, Y7.57) and the cytoplasmic polar network (R6.37, R7.57, N7.61, E8.49) reorganise during activation, transmitting the extracellular signal to the G protein interface.

Comparisons of ligand-free and peptide-bound structures reveal that the intracellular half of the TMD aligns well between states, while the extracellular half is structurally divergent and exhibits receptor-specific conformations in the absence of ligand. This asymmetry suggests that Gs coupling pre-organises the intracellular region, lowering the energetic barrier for peptide binding and receptor activation.

A notable difference among the receptors concerns intracellular loop 2 (ICL2). In GCGR, ICL2 forms extensive contacts with Gs, contributing an interface area of 799 Ų, significantly larger than GLP-1R (396 Ų) or GIPR (416 Ų). The GCGR–Gi structure further reveals that ICL2 shifts away from Gi, resulting in limited contact—a distinct binding mode compared to Gs coupling. These differences in ICL2 engagement likely contribute to the differential G protein coupling profiles of the incretin receptors.

Implications for Therapeutic Design

The structural insights from cryo-EM have direct implications for the design of next-generation incretin therapeutics. The identification of ECL3 as a bias switch suggests that rational modification of peptide N-termini could tune signalling profiles toward G protein-biased activation, potentially enhancing therapeutic efficacy while reducing β-arrestin-mediated desensitisation. The receptor-specific residues in the upper TMD pocket that discriminate between GIP and GLP-1 provide templates for engineering selectivity.

The structural characterisation of dual and triple agonists bound to their receptor targets reveals how these peptides achieve polypharmacology. The conserved binding mode across receptors allows a single peptide to engage multiple targets, while receptor-specific dynamics in the extracellular loops accommodate sequence variations that fine-tune potency and efficacy. As the field moves toward increasingly complex multi-agonist therapeutics, cryo-EM structures will remain essential for understanding and optimising their mechanisms of action.